The potential of the antiplatelet agent ticagrelor as a new antibacterial agent


Autores/as

  • Risa-Ueda Hamamatsu University School of Medicine
  • Hiromitsu-Kataoka, MD Hamamatsu University School of Medicine

DOI:

https://doi.org/10.22517/25395203.25126

Palabras clave:

Ticagrelor, pharmacology, antibacterial resistance, antiplatelet, MRSA, antibiotic.

Resumen

The number of deaths caused by drug-resistant bacteria is expected to increase in the future, and there is a need to develop new antimicrobial agents. Recently, the antiplatelet drug ticagrelor has been reported to have promising antibacterial properties. The purpose of this review is to analyze articles and case reports that describe the antimicrobial action of ticagrelor. Ticagrelor was found to have antibacterial reactions against Gram-positive bacteria, including drug-resistant and spore-forming bacteria, while no effect was observed against Gram-negative bacteria. In this paper we discuss a new potential antimicrobial agent, ticagrelor.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Risa-Ueda, Hamamatsu University School of Medicine

Medical student

Hiromitsu-Kataoka, MD, Hamamatsu University School of Medicine

MD

Cardiology physician

Internal Medicine 3rd Division, Department of Cardiology

Citas

World Health Organization. global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. [Internet] 2016 [cited 09 July 2019]. Available from: https://www.doherty.edu.au/news-events/news/who-global-priority-pathogens-list-of-antibiotic-resistant-bacteria

O’Neill J. Tackling drug-resistant infections globally: Final report and recommen- dations. Rev Antimicrob Resist. 2016;84

Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, McCarthy N, Paul P, McDonald LC, Kallen A, Fiore A, Craig M, Baggs J. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med. 2020 Apr 2;382(14):1309-1319. doi: 10.1056/NEJMoa1914433

Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4.

Ministry of Health Japan. Work and Welfare. Nippon AMR One Health Report (NAOR) 2020.

Lancellotti P, Musumeci L, Jacques N, Servais L, Goffin E, Pirotte B, Oury C. Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. JAMA Cardiol. 2019 Jun 1;4(6):596-599. doi: 10.1001/jamacardio.2019.1189

Phanchana M, Phetruen T, Harnvoravongchai P, Raksat P, Ounjai P, Chankhamhaengdecha S, Janvilisri T. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci Rep. 2020 Apr 16;10(1):6497. doi: 10.1038/s41598-020-63199-x

Rigatelli G, Zuin M, Rigatelli A, Conte L, Roncon L. Protective activity of Ticagrelor against bacterial infection in acute myocardial infarction patients. Eur J Intern Med. 2019 Dec;70:e19-e21. doi: 10.1016/j.ejim.2019.10.011.

Jean SS, Hsueh SC, Hwang JJ, Hsueh PR. Ticagrelor: A promising role in preventing multi-organ failure among patients with sepsis due to resistant gram-positive cocci. J Microbiol Immunol Infect. 2019 Aug;52(4):513-515. doi: 10.1016/j.jmii.2019.06.004.

Dalén M, Biancari F; E-CABG Study Group Collaborators. Infectious complications in patients receiving ticagrelor or clopidogrel before coronary artery bypass grafting. J Hosp Infect. 2020 Feb;104(2):236-238. doi: 10.1016/j.jhin.2019.09.018.

Goffin E, Jacques N, Musumeci L, Nchimi A, Oury C, Lancellotti P, Pirotte B. Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity. Eur J Med Chem. 2020 Dec 15;208:112767. doi: 10.1016/j.ejmech.2020.112767.

Hannachi N, Grac L, Baudoin JP, Fournier PE, Habib G, Camoin-Jau L. Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. Int J Antimicrob Agents. 2020 Mar;55(3):105890. doi: 10.1016/j.ijantimicag.2020.105890

Hussar DA, Schartel AF. Rivaroxaban, ticagrelor, and fidaxomicin. J Am Pharm Assoc (2003). 2011 Nov-Dec;51(6):778-82. doi: 10.1331/JAPhA.2011.11548.

Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013 Apr;69(4):877-83. doi: 10.1007/s00228-012-1436-x.

Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009 Winter;27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327.

Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014;25(7):517-25. doi: 10.3109/09537104.2013.842965.

Sexton TR, Zhang G, Macaulay TE, Callahan LA, Charnigo R, Vsevolozhskaya OA, Li Z, Smyth S. Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia. JACC Basic Transl Sci. 2018 Aug 28;3(4):435-449. doi: 10.1016/j.jacbts.2018.05.005

Si D, Rajmokan M, Lakhan P, Marquess J, Coulter C, Paterson D. Surgical site infections following coronary artery bypass graft procedures: 10 years of surveillance data. BMC Infect Dis. 2014 Jun 10;14:318. doi: 10.1186/1471-2334-14-318.

Descargas

Publicado

2023-06-29 — Actualizado el 2023-08-02

Versiones

Cómo citar

Ueda, R., & Kataoka, H. (2023). The potential of the antiplatelet agent ticagrelor as a new antibacterial agent. Revista Médica De Risaralda, 29(1). https://doi.org/10.22517/25395203.25126 (Original work published 29 de junio de 2023)

Número

Vol. 29 Núm. 1 (2023): Enero-junio 2023

Sección

Revisión Sistemática de Literatura

Licencia

Cesión de derechos y tratamiento de datos

La aceptación de un artículo para su publicación en la Revista Médica de Risaralda implica la cesión de los derechos de impresión y reproducción, por cualquier forma y medio, del autor a favor de  Facultad de Ciencias de la Salud de la Universidad Tecnológica de Pereira. 1995-2018. Todos los derechos reservados ®

por parte de los autores para obtener el permiso de reproducción de sus contribuciones. La reproducción total o parcial de los trabajos aparecidos en la Revista Médica de Risaralda, debe hacerse citando la procedencia, en caso contrario, se viola los derechos reservados.

Asimismo, se entiende que los conceptos y opiniones expresados en cada trabajo son de la exclusiva responsabilidad del autor, sin responsabilizarse ni solidarizarse, necesariamente, ni la redacción, ni la editorial.

Es responsabilidad de los autores poder proporcionar a los lectores interesados copias de los datos en bruto, manuales de procedimiento, puntuaciones y, en general, material experimental relevante.

Asimismo, la Dirección de la revista garantiza el adecuado tratamiento de los datos de carácter personal